Latest News

21 November 2017

Antibiotic-resistant Mycoplasma genitalium may soon be as great a health risk as chlamydia

According to health professionals, Mycoplasma genitalium is developing resistance to antibiotics at an alarming rate. Much like chlamydia, many people...

Read More

10 November 2017

SpeeDx is transforming global health outcomes

SpeeDx has significantly contributed to the success and development of the Australian MedTech industry. The CSIRO’s Medical Technologies and Pharmaceutical...

Read More

8 November 2017

Elisa Mokany – winner of the “Outstanding Achievement” Medtech Industry award

We are happy to announce our Chief Technology Officer, Elisa Mokany, has won the "Outstanding Achievement" award at the Medical...

Read More

26 October 2017

PlexPCR^® VHS | HSV-1&2, VZV TP | Receives CE-Marking

SpeeDx Multiplexed VZV, Herpes, Syphilis Assay Receives CE-IVD Mark SpeeDx Pty. Ltd. has announced that it has received CE-IVD marking for...

Read More

25 October 2017

True Leaders Game Changers 2017 – Alison Todd

SpeeDx's Alison Todd frontline fighter in the war on superbugs Alison Todd co-founded SpeeDx with Elisa Mokany in 2008. The company...

Read More

25 September 2017

Mycoplasma genitalium macrolide resistance in QLD

The macrolide azithromycin is recommended for treatment of Mycoplasma genitalium infection; however, M. genitalium strains possessing macrolide resistance-mediating mutations (MRMMs)...

Read More